Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Complete Genome Sequence of a Pseudomonas aeruginosa Isolate from a Kidney Stone.

Johnson G, Stark N, Wolfe AJ, Putonti C.

Microbiol Resour Announc. 2019 Sep 19;8(38). pii: e01073-19. doi: 10.1128/MRA.01073-19.

2.

Draft Genome Sequences of 11 Lactobacillus jensenii Strains Isolated from the Female Bladder.

Putonti C, Ahmad A, Baddoo G, Diaz J, Do M, Gallian N, Lorentzen C, Mohammed H, Murphy J, Olu-Ajeigbe A, Yang T, Miller-Ensminger T, Stark N, Maskeri L, Van Dusen J, Wolfe AJ.

Microbiol Resour Announc. 2019 Aug 29;8(35). pii: e00970-19. doi: 10.1128/MRA.00970-19.

3.

Functionalized Cellulose Nanocrystals: A Potential Fire Retardant for Polymer Composites.

Bajwa DS, Rehovsky C, Shojaeiarani J, Stark N, Bajwa S, Dietenberger MA.

Polymers (Basel). 2019 Aug 18;11(8). pii: E1361. doi: 10.3390/polym11081361.

4.

Soldier as Teacher: the Impact of the Army's Innovations in Behavioral Healthcare Delivery on the Training of All Psychiatrists.

Accordino R, Ivany C, Stark N, Brown M.

Acad Psychiatry. 2019 Jun;43(3):312-314. doi: 10.1007/s40596-019-01063-5. Epub 2019 May 7. No abstract available.

PMID:
31066009
5.

A close look at therapist contributions to narrative-emotion shifting in a case illustration of brief dynamic therapy .

Friedlander ML, Angus LE, Xu M, Wright ST, Stark NM.

Psychother Res. 2019 May 6:1-15. doi: 10.1080/10503307.2019.1609710. [Epub ahead of print]

PMID:
31057078
6.

Correction: Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells.

Kramer D, Stark N, Schulz-Heddergott R, Erytch N, Edmunds S, Roßmann L, Bastians H, Concin N, Moll UM, Dobbelstein M.

Cell Death Differ. 2019 Mar;26(4):780. doi: 10.1038/s41418-018-0190-8.

7.

Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.

Schulz-Heddergott R, Stark N, Edmunds SJ, Li J, Conradi LC, Bohnenberger H, Ceteci F, Greten FR, Dobbelstein M, Moll UM.

Cancer Cell. 2018 Aug 13;34(2):298-314.e7. doi: 10.1016/j.ccell.2018.07.004.

8.

Spin-coating: A new approach for improving dispersion of cellulose nanocrystals and mechanical properties of poly (lactic acid) composites.

Shojaeiarani J, Bajwa DS, Stark NM.

Carbohydr Polym. 2018 Jun 15;190:139-147. doi: 10.1016/j.carbpol.2018.02.069. Epub 2018 Feb 23.

PMID:
29628231
9.

Prevalence and predictors of persistent post-surgical opioid use: a prospective observational cohort study.

Stark N, Kerr S, Stevens J.

Anaesth Intensive Care. 2017 Nov;45(6):700-706.

10.

Weathering Characteristics of Wood Plastic Composites Reinforced with Extracted or Delignified Wood Flour.

Chen Y, Stark NM, Tshabalala MA, Gao J, Fan Y.

Materials (Basel). 2016 Jul 23;9(8). pii: E610. doi: 10.3390/ma9080610.

11.

Chemical modification of nanocellulose with canola oil fatty acid methyl ester.

Wei L, Agarwal UP, Hirth KC, Matuana LM, Sabo RC, Stark NM.

Carbohydr Polym. 2017 Aug 1;169:108-116. doi: 10.1016/j.carbpol.2017.04.008. Epub 2017 Apr 4.

PMID:
28504126
12.

A Project Team Analysis Using Tuckman's Model of Small-Group Development.

Natvig D, Stark NL.

J Nurs Educ. 2016 Dec 1;55(12):675-681. doi: 10.3928/01484834-20161114-03.

PMID:
27893902
13.

Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells.

Kramer D, Stark N, Schulz-Heddergott R, Erytch N, Edmunds S, Roßmann L, Bastians H, Concin N, Moll UM, Dobbelstein M.

Cell Death Differ. 2017 Feb;24(2):300-316. doi: 10.1038/cdd.2016.124. Epub 2016 Nov 11. Erratum in: Cell Death Differ. 2019 Mar;26(4):780.

14.

An Open Trial of Lurasidone as an Acute and Maintenance Adjunctive Treatment for Outpatients With Treatment-Resistant Bipolar Disorder: Response to Letter to the Editors.

Schaffer CB, Schaffer LC, Nordahl TE, Stark NM, Gohring CE.

J Clin Psychopharmacol. 2016 Oct;36(5):522-3. doi: 10.1097/JCP.0000000000000567. No abstract available.

PMID:
27518477
15.

An Open Trial of Lurasidone as an Acute and Maintenance Adjunctive Treatment for Outpatients With Treatment-Resistant Bipolar Disorder.

Schaffer CB, Schaffer LC, Nordahl TE, Stark NM, Gohring CE.

J Clin Psychopharmacol. 2016 Feb;36(1):88-9. doi: 10.1097/JCP.0000000000000450. No abstract available.

PMID:
26650972
16.

Reduction of 30-Day Preventable Pediatric Readmission Rates With Postdischarge Phone Calls Utilizing a Patient- and Family-Centered Care Approach.

Flippo R, NeSmith E, Stark N, Joshua T, Hoehn M.

J Pediatr Health Care. 2015 Nov-Dec;29(6):492-500. doi: 10.1016/j.pedhc.2015.01.010. Epub 2015 Mar 7.

PMID:
25753256
17.

Grafting of bacterial polyhydroxybutyrate (PHB) onto cellulose via in situ reactive extrusion with dicumyl peroxide.

Wei L, McDonald AG, Stark NM.

Biomacromolecules. 2015 Mar 9;16(3):1040-9. doi: 10.1021/acs.biomac.5b00049. Epub 2015 Feb 18.

PMID:
25664869
18.

Oxidative-induction time as a measure of vitamin E concentration in ultra-high molecular weight polyethylene.

Heuer EG, Braithwaite GJ, Miller BL, Spiegelberg SH, Gsell RA, Rufner AS, Stark N.

J Biomed Mater Res B Appl Biomater. 2015 Jan;103(1):106-15. doi: 10.1002/jbm.b.33175. Epub 2014 Apr 28.

PMID:
24771508
19.

Evaluation of the prevalence and prospective clinical impact of the JAK2 V617F mutation in coronary patients.

Muendlein A, Gasser K, Kinz E, Stark N, Leiherer A, Rein P, Saely CH, Grallert H, Peters A, Drexel H, Lang AH.

Am J Hematol. 2014 Mar;89(3):295-301. doi: 10.1002/ajh.23632. Epub 2014 Feb 18.

20.

A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer.

Lesser GJ, Case D, Stark N, Williford S, Giguere J, Garino LA, Naughton MJ, Vitolins MZ, Lively MO, Shaw EG; Wake Forest University Community Clinical Oncology Program Research Base.

J Support Oncol. 2013 Mar;11(1):31-42.

21.

A common variant of the MACC1 gene is significantly associated with overall survival in colorectal cancer patients.

Lang AH, Geller-Rhomberg S, Winder T, Stark N, Gasser K, Hartmann B, Kohler B, Grizelj I, Drexel H, Muendlein A.

BMC Cancer. 2012 Jan 17;12:20. doi: 10.1186/1471-2407-12-20.

22.

Identification of hypoxia-induced genes in human SGBS adipocytes by microarray analysis.

Geiger K, Leiherer A, Muendlein A, Stark N, Geller-Rhomberg S, Saely CH, Wabitsch M, Fraunberger P, Drexel H.

PLoS One. 2011;6(10):e26465. doi: 10.1371/journal.pone.0026465. Epub 2011 Oct 19.

23.

Are AHSG polymorphisms directly associated with coronary atherosclerosis?

Muendlein A, Stark N, Rein P, Saely CH, Geller-Rhomberg S, Geiger K, Vonbank A, Drexel H.

Clin Chim Acta. 2012 Jan 18;413(1-2):287-90. doi: 10.1016/j.cca.2011.10.008. Epub 2011 Oct 15.

PMID:
22024217
24.

Validity and reliability of the Omron HJ-303 tri-axial accelerometer-based pedometer.

Steeves JA, Tyo BM, Connolly CP, Gregory DA, Stark NA, Bassett DR.

J Phys Act Health. 2011 Sep;8(7):1014-20.

PMID:
21885893
25.

Separation of anti-neoplastic activities by fractionation of a Pluchea odorata extract.

Bauer S, Singhuber J, Seelinger M, Unger C, Viola K, Vonach C, Giessrigl B, Madlener S, Stark N, Wallnofer B, Wagner KH, Fritzer-Szekeres M, Szekeres T, Diaz R, Tut F, Frisch R, Feistel B, Kopp B, Krupitza G, Popescu R.

Front Biosci (Elite Ed). 2011 Jun 1;3:1326-36.

PMID:
21622139
26.

Hypoxia induces apelin expression in human adipocytes.

Geiger K, Muendlein A, Stark N, Saely CH, Wabitsch M, Fraunberger P, Drexel H.

Horm Metab Res. 2011 Jun;43(6):380-5. doi: 10.1055/s-0031-1273767. Epub 2011 Mar 29.

27.

Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF.

Lang AH, Drexel H, Geller-Rhomberg S, Stark N, Winder T, Geiger K, Muendlein A.

J Mol Diagn. 2011 Jan;13(1):23-8. doi: 10.1016/j.jmoldx.2010.11.007. Epub 2010 Dec 23.

28.

Multifactorial anticancer effects of digalloyl-resveratrol encompass apoptosis, cell-cycle arrest, and inhibition of lymphendothelial gap formation in vitro.

Madlener S, Saiko P, Vonach C, Viola K, Huttary N, Stark N, Popescu R, Gridling M, Vo NT, Herbacek I, Davidovits A, Giessrigl B, Venkateswarlu S, Geleff S, Jäger W, Grusch M, Kerjaschki D, Mikulits W, Golakoti T, Fritzer-Szekeres M, Szekeres T, Krupitza G.

Br J Cancer. 2010 Apr 27;102(9):1361-70. doi: 10.1038/sj.bjc.6605656.

29.

A polar extract of the Maya healing plant Anthurium schlechtendalii (Aracea) exhibits strong in vitro anticancer activity.

Stark N, Gridling M, Madlener S, Bauer S, Lackner A, Popescu R, Diaz R, Tut FM, Vo TP, Vonach C, Giessrigl B, Saiko P, Grusch M, Fritzer-Szekeres M, Szekeres T, Kopp B, Frisch R, Krupitza G.

Int J Mol Med. 2009 Oct;24(4):513-21.

PMID:
19724892
30.

In vitro anti-neoplastic activity of the ethno-pharmaceutical plant Hypericum adenotrichum Spach endemic to Western Turkey.

Ozmen A, Bauer S, Gridling M, Singhuber J, Krasteva S, Madlener S, Vo TP, Stark N, Saiko P, Fritzer-Szekeres M, Szekeres T, Askin-Celik T, Krenn L, Krupitza G.

Oncol Rep. 2009 Oct;22(4):845-52.

PMID:
19724864
31.

Pro- and anticarcinogenic mechanisms of piceatannol are activated dose dependently in MCF-7 breast cancer cells.

Vo NT, Madlener S, Bago-Horvath Z, Herbacek I, Stark N, Gridling M, Probst P, Giessrigl B, Bauer S, Vonach C, Saiko P, Grusch M, Szekeres T, Fritzer-Szekeres M, Jäger W, Krupitza G, Soleiman A.

Carcinogenesis. 2010 Dec;31(12):2074-81. doi: 10.1093/carcin/bgp199. Epub 2009 Aug 20.

PMID:
19696164
32.

In vitro anti-leukemic activity of the ethno-pharmacological plant Scutellaria orientalis ssp. carica endemic to western Turkey.

Ozmen A, Madlener S, Bauer S, Krasteva S, Vonach C, Giessrigl B, Gridling M, Viola K, Stark N, Saiko P, Michel B, Fritzer-Szekeres M, Szekeres T, Askin-Celik T, Krenn L, Krupitza G.

Phytomedicine. 2010 Jan;17(1):55-62. doi: 10.1016/j.phymed.2009.06.001. Epub 2009 Jul 2.

PMID:
19576743
33.

In vitro anti-cancer activity of two ethno-pharmacological healing plants from Guatemala Pluchea odorata and Phlebodium decumanum.

Gridling M, Stark N, Madlener S, Lackner A, Popescu R, Benedek B, Diaz R, Tut FM, Nha Vo TP, Huber D, Gollinger M, Saiko P, Ozmen A, Mosgoeller W, De Martin R, Eytner R, Wagner KH, Grusch M, Fritzer-Szekeres M, Szekeres T, Kopp B, Frisch R, Krupitza G.

Int J Oncol. 2009 Apr;34(4):1117-28.

PMID:
19287970
34.

Health-related quality of life in long-term breast cancer survivors: differences by adjuvant chemotherapy dose in Cancer and Leukemia Group B study 8541.

Paskett E, Herndon J 2nd, Donohue K, Naughton M, Grubbs S, Pavy M, Hensley M, Stark N, Kornblith A, Bittoni M; for Cancer and Leukemia Group B.

Cancer. 2009 Mar 1;115(5):1109-20. doi: 10.1002/cncr.24140.

35.

Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804.

Paskett ED, Herndon JE 2nd, Day JM, Stark NN, Winer EP, Grubbs SS, Pavy MD, Shapiro CL, List MA, Hensley ML, Naughton MA, Kornblith AB, Habin KR, Fleming GF, Bittoni MA; Cancer and Leukemia Group B.

Psychooncology. 2008 Nov;17(11):1108-20. doi: 10.1002/pon.1329.

36.

Stilbene analogues affect cell cycle progression and apoptosis independently of each other in an MCF-7 array of clones with distinct genetic and chemoresistant backgrounds.

Bader Y, Madlener S, Strasser S, Maier S, Saiko P, Stark N, Popescu R, Huber D, Gollinger M, Erker T, Handler N, Szakmary A, Jäger W, Kopp B, Tentes I, Fritzer-Szekeres M, Krupitza G, Szekeres T.

Oncol Rep. 2008 Mar;19(3):801-10.

PMID:
18288419
37.

Treatment of low-risk myelodysplastic syndromes with high-dose daily oral cholecalciferol (2000-4000 IU vitamin D(3)).

Molnár I, Stark N, Lovato J, Powell BL, Cruz J, Hurd DD, Mathieu JS, Chen TC, Holick MF, Cambra S, McQuellon RP, Schwartz GG.

Leukemia. 2007 May;21(5):1089-92. Epub 2007 Mar 8. No abstract available.

PMID:
17344922
38.

Cancer screening among Native Americans in eastern North Carolina.

Farmer DF, Bell RA, Stark N.

J Health Care Poor Underserved. 2005 Nov;16(4):634-42.

PMID:
16311489
39.

Increased arterial wave reflections predict severe cardiovascular events in patients undergoing percutaneous coronary interventions.

Weber T, Auer J, O'rourke MF, Kvas E, Lassnig E, Lamm G, Stark N, Rammer M, Eber B.

Eur Heart J. 2005 Dec;26(24):2657-63. Epub 2005 Sep 23.

PMID:
16183688
40.

Economic outcomes of breast cancer survivorship: CALGB study 79804.

Hensley ML, Dowell J, Herndon JE 2nd, Winer E, Stark N, Weeks JC, Paskett E.

Breast Cancer Res Treat. 2005 May;91(2):153-61.

PMID:
15868443
41.

[Predictive value of teller Acuity Card Test (TACT) and comparison of recognition and grating acuities in premature children with and without residua of Retinopathy of Prematurity (ROP)].

Zubcov AA, Rossillion BM, Kacer B, Stärk N, Schlösser R, Vanselow K.

Klin Monbl Augenheilkd. 2002 Oct;219(10):722-7. German.

PMID:
12447716
42.

Understanding biological safety.

Stark N.

Med Device Technol. 2002 Sep;13(7):28-31.

PMID:
12397832
43.

Hyperbaric oxygen therapy for cognitive disorders after irradiation of the brain.

Hulshof MC, Stark NM, van der Kleij A, Sminia P, Smeding HM, Gonzalez Gonzalez D.

Strahlenther Onkol. 2002 Apr;178(4):192-8.

PMID:
12040756
44.

Clinical trial enrollment of rural patients with cancer.

Paskett ED, Cooper MR, Stark N, Ricketts TC, Tropman S, Hatzell T, Aldrich T, Atkins J.

Cancer Pract. 2002 Jan-Feb;10(1):28-35.

PMID:
11866706
45.

Implications of the situated learning model for teaching and learning nursing research.

Gieselman JA, Stark N, Farruggia MJ.

J Contin Educ Nurs. 2000 Nov-Dec;31(6):263-8; quiz 284-5.

PMID:
11865859
46.

Increasing participation of minorities in cancer clinical trials: summary of the "Moving Beyond the Barriers" Conference in North Carolina.

Stark N, Paskett E, Bell R, Cooper MR, Walker E, Wilson A, Tatum C.

J Natl Med Assoc. 2002 Jan;94(1):31-9. Review.

47.

Prostate cancer as a public health issue in North Carolina.

Stark N, Paskett E, Demark-Wahnefried W, Carbone E, Godley P.

N C Med J. 2001 Sep-Oct;62(5):286-90. No abstract available.

PMID:
11570328
48.

'What do they know about it?' How the North Carolina public views cancer clinical trials: implications for primary care doctors.

Randall-David B, Stark N, Gierisch J, Torti F.

N C Med J. 2001 Sep-Oct;62(5):281-5. No abstract available.

PMID:
11570327
49.

Lymphedema: Knowledge, Treatment, and Impact Among Breast Cancer Survivors.

Paskett ED, Stark N.

Breast J. 2000 Nov;6(6):373-378.

PMID:
11348395
50.

[Threshold value retinopathy of prematurity. Visual outcome of 2-year-old children after cryocoagulation].

Vanselow K, Kaiser P, Stärk N, Schlösser R, Zubcov A.

Ophthalmologe. 1999 Dec;96(12):786-91. German.

PMID:
10643312

Supplemental Content

Support Center